NCT02911467 (MR) is a Phase 1 clinical trial of Pyruvate (13C) in Prostate Cancer, sponsored by Rahul Aggarwal.

Who is sponsoring NCT02911467?

NCT02911467 is sponsored by Rahul Aggarwal.

What drugs are being tested in NCT02911467?

Interventions in NCT02911467: Pyruvate (13C), MRI.

What condition does NCT02911467 study?

NCT02911467 studies Prostate Cancer.

Is NCT02911467 still recruiting?

NCT02911467 is currently terminated. Last updated 24 July 2020.

Last reviewed 2020-07-24 · How we verify

NCT02911467: MR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer

Terminated Phase 1 Last updated 24 July 2020

What this trial tests

Phase 1 trial testing Pyruvate (13C) in Prostate Cancer in 8 participants. Terminated before completion.

Timeline

8 November 2016

Primary endpoint
20 July 2020

20 July 2020

Quick facts

Lead sponsor	Rahul Aggarwal
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	8
Start date	8 November 2016
Primary completion	20 July 2020
Estimated completion	20 July 2020
Sites	1 location across United States

Drugs / interventions tested

Pyruvate (13C) — full drug profile →
MRI — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Rahul Aggarwal — full company profile →

Who can join

18 and older, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.
Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, et al · · 2019 · cited 332× · PMID 30472500 · DOI 10.1016/j.neo.2018.09.006
Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients.
Larson PEZ, Chen HY, Gordon JW, Korn N, et al · · 2018 · cited 94× · PMID 30230646 · DOI 10.1002/nbm.3997
Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study.
Chen HY, Aggarwal R, Bok RA, Ohliger MA, et al · · 2020 · cited 74× · PMID 31685983 · DOI 10.1038/s41391-019-0180-z
Neuroendocrine and Aggressive-Variant Prostate Cancer.
Spetsieris N, Boukovala M, Patsakis G, Alafis I, et al · · 2020 · cited 62× · PMID 33339136 · DOI 10.3390/cancers12123792
The Role of Lactate Metabolism in Prostate Cancer Progression and Metastases Revealed by Dual-Agent Hyperpolarized 13C MRSI.
Bok R, Lee J, Sriram R, Keshari K, et al · · 2019 · cited 48× · PMID 30813322 · DOI 10.3390/cancers11020257
Magnetic resonance imaging with hyperpolarized agents: methods and applications.
Adamson EB, Ludwig KD, Mummy DG, Fain SB. · · 2017 · cited 32× · PMID 28384123 · DOI 10.1088/1361-6560/aa6be8
Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.
Chetta P, Zadra G. · · 2021 · cited 27× · PMID 35582011 · DOI 10.20517/cdr.2020.54
Metabolic response to radiation therapy in cancer.
Read GH, Bailleul J, Vlashi E, Kesarwala AH. · · 2022 · cited 25× · PMID 34961986 · DOI 10.1002/mc.23379

Verify or expand the search:

Other trials of Pyruvate (13C)

Trials testing the same drug.

NCT02913131 — Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies · Phase 1, PHASE2 · terminated

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Rahul Aggarwal trials

Trials by the same sponsor.

NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
NCT05888532 — 64Cu-GRIP B in Patients With Advanced Malignancies · Phase 1, PHASE2 · recruiting
NCT04926181 — Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer · Phase 2 · terminated
NCT05011188 — FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer · Phase 1, PHASE2 · active not recruiting
NCT04927663 — 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02911467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rahul Aggarwal
Last refreshed: 24 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02911467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing